Â鶹´«Ã½¸ßÇå

Conversational Speech Analysis (CSA) Study (18-0456)

• Investigator: Peter Pressman, MD
• Purpose: to learn more about how speech changes over time in adult populations, understand how those changes reflect changes in cognition, and develop new ways of detecting Mild Cognitive Impairment (MCI) and dementia using everyday speech.
• Timeline: two study visits, one year apart.
• Study flyer:
• Key Eligibility Criteria:
  • Age: 40-95 years old
  • Diagnosis: Mild Cognitive Impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder

Facial Expressions Study (17-0599)

• Investigator: Peter Pressman, MD
• Purpose: to understand how the brain makes different facial expressions using high speed videography, learn more about how neurological disorders may impact a person’s facial movements and expressions, and develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
• Timeline: one study visit that will last approximately one hour.
• CUACC Website: click here
• Key Eligibility Criteria:
  • Age: 18-75 years old
  • Diagnosis: Mild Cognitive Impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder
  • Are right handed.

SESAD (19-2727) 

• Investigator: Peter Pressman, MD
• Purpose: to learn more about the safety and effectiveness of a drug called sargramostim for improving cognitive function and memory in people with Alzheimer’s Disease (AD).
• Intervention: if determined to be eligible during screening, you will be assigned to one of two arms of the study: 1) receives study medication; 2) receives placebo (a pill or a liquid that looks like medicine but is not real).
  
• Timeline: after initial screenings at the CU Anschutz campus in Aurora, CO, participants will be able to have weekly home nursing visits to provide supplies and draw blood. Occasional visits to campus during the study will be required for procedures that cannot be done at home. Including screening and follow-up, study participation last up to 9-1/2 months with up to 55 visits.
  • Screening period will last up to 8 weeks
  • Treatment period will last 24 weeks
  • Follow-up visit occurs 45 days after end of treatment
• Compensation: study related care and medication at no cost.
• : https://www.ucdenver.edu/docs/librariesprovider61/clinical-research-pdfs/sargramostim-ad-26sep2023_approved.pdf
• ClinicalTrials.gov Identifier:
• Key Eligibility Criteria:
  • Age: between 60-85 years old
  • Diagnosis: mild-to-moderate Alzheimer’s disease (AD)
  • Have a study partner with whom you at least 12 hours of contact a week and is willing to attend scheduled visits, can report changes in your thinking and memory, and is willing to be trained to give daily injections of study drug
  • Willing to have testing of sample collected from a lumbar puncture/spinal tap or an amyloid PET scan to confirm diagnosis of Alzheimer’s disease
  • Must not have a first degree relative diagnosed with AD before 55 years of age
    

Linda Crnic Institute for Down Syndrome Research Studies

ALLFTD (21-2833)

• Investigator:  Peter Pressman, MD
• Purpose: the ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and informing clinical trial design (Biofluid-Focused and Longitudinal arms available).
• ClinicalTrials.gov Identifier: 

• ALLFTD Biofluid Timeline: one-time visit with questionnaires, neurological exam, blood drawn, and optional lumbar puncture.
• Biofluid Key Eligibility Criteria:
  • Age: 18+ years old
  • Diagnosis: FTLD syndrome like bvFTD, bvFTD with ALS, PPA, PSP, or CBD

• ALLFTD Longitudinal Timeline: annual visit to the clinic, each lasting 2–3 days, with questionnaires, thinking and memory questions, neurological exam, blood drawn, and an MRI.
  
• Longitudinal Key Eligibility Criteria:
  • Age: 18+ years old
  • Diagnosis: FTLD syndrome like bvFTD, bvFTD with ALS, PPA, PSP, or CBD, OR are from a family with a mutation in a gene known tocause FTLD (such as C9orf72, MAPT, and GRN) OR have a significant family history of FTLD suggesting a familial genetic mutation
    

Conversational Speech Analysis (CSA) Study (18-0456)

• Investigator: Peter Pressman, MD
• Purpose: to learn more about how speech changes over time in adult populations, understand how those changes reflect changes in cognition, and develop new ways of detecting Mild Cognitive Impairment (MCI) and dementia using everyday speech.
• Timeline: two study visits, one year apart.
• Study flyer:
• Key Eligibility Criteria:
  • Age: 40-95 years old
  • Diagnosis: Mild Cognitive Impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder

Facial Expressions Study (17-0599)

• Investigator: Peter Pressman, MD
• Purpose: to understand how the brain makes different facial expressions using high speed videography, learn more about how neurological disorders may impact a person’s facial movements and expressions, and develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
• Timeline: one study visit that will last approximately one hour.
• CUACC Website: click here
• Key Eligibility Criteria:
  • Age: 18-75 years old
  • Diagnosis: Mild Cognitive Impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder
  • Are right handed

Facial Expressions Study (17-0599)

• Investigator: Peter Pressman, MD
• Purpose: to understand how the brain makes different facial expressions using high speed videography, learn more about how neurological disorders may impact a person’s facial movements and expressions, and develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
• Timeline: one study visit that will last approximately one hour.
• CUACC Website: click here
• Key Eligibility Criteria:
  • Age: 18-75 years old
  • Diagnosis: Mild Cognitive Impairment (MCI) or dementia or have NOT been diagnosed with a memory disorder
  • Are right handed

RewinD-LB (23-0426)

• Investigator: 
• Purpose: to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with Dementia with Lewy Bodies (DLB). More specifically, the aim of this study is to find out if the participant experiences any improvement in verbal learning, memory, attention, and cognitive and functional performance.
• Intervention: neflamapimod (50% chance) or placebo (50% chance).
• Timeline: 8 in-person clinic visits (or 9 visits if an additional Screening Visit is scheduled) over approximately 21 weeks.  Participant will be asked to return to the clinic for a Follow-Up Visit 2 weeks after their last dose of study drug.  If the participant decides to participate in the Open-Label Extension Phase, where all subjects will receive neflamapimod, they will have 5 additional clinic visits over 34 weeks.
• ClinicalTrials.gov Identifier:  
• Key Eligibility Criteria:
  • Age: ≥ 55 years old
  • Diagnosis: Dementia with Lewy Bodies (DLB)
    

SHIMMER (22-0669)

• Investigator: Samantha Holden, MD
• Purpose: to learn about the safety of CT1812 and how well your body tolerates a once-a-day dose of CT1812. The study will also test how well CT1812 will treat mild to moderate dementia with Lewy Bodies (DLB).
• Intervention: low dose of CT1812 (33% chance), high dose of CT1812 (33% chance) or placebo (33% chance).
• Timeline: 12 in-person study visits over 210 days.
• Clinicaltrials.gov:  
• Key Eligibility Criteria:
  • Age: 50-85 years old
  • Diagnosis: Dementia with Lewy Bodies (DLB)
  • Have a reliable support person or caregiver willing to participate
  • Willingness to undergo 2 lumbar punctures
    

Conversational Speech Analysis (CSA) Study (18-0456)

• Investigator: Peter Pressman, MD
• Purpose: to learn more about how speech changes over time in adult populations, understand how those changes reflect changes in cognition, and develop new ways of detecting Mild Cognitive Impairment (MCI) and dementia using everyday speech.
• Timeline: two study visits, one year apart.
• Study flyer:
• Key Eligibility Criteria:
  • Age: 40-95 years old
  • Diagnosis: Mild Cognitive Impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder
    

Facial Expressions Study (17-0599)

• Investigator: Peter Pressman, MD
• Purpose: to understand how the brain makes different facial expressions using high speed videography, learn more about how neurological disorders may impact a person’s facial movements and expressions, and develop the groundwork for a diagnostic tool that would detect differences between a person’s facial movements/expressions and their emotions.
• Timeline: one study visit that will last approximately one hour.
• CUACC Website: click here
• Key Eligibility Criteria:
  • Age: 18-75 years old
  • Diagnosis: Mild Cognitive Impairment (MCI) or dementia OR have NOT been diagnosed with a memory disorder
  • Are right handed